Recombinant Dopamine Receptor D2 (DRD2) Mus musculus (Mouse) Recombinant protein

DR-D2; D2DR; D2R

Add to Cart Distributors
Overview
Properties
  • Source Prokaryotic expression, Host E.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationSecreted
  • Molecular Mass 29.8kDa, Accurate 28kDa(Analysis of differences refer to the manual)
  • Residues & TagsSer194~Ala421 with N-terminal His Tag
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Traits Freeze-dried powder, Purity > 90%
  • Isoelectric Point10.4
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Recombinant Dopamine Receptor D2 (DRD2) Packages (Simulation)
  • Recombinant Dopamine Receptor D2 (DRD2) Packages (Simulation)
  • Recombinant Dopamine Receptor D2 (DRD2) Figure . Gene Sequencing (extract)
  • RPA673Mu01.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Sequence

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Distinct patterns of outcome valuation and amygdala-prefrontal cortex synaptic remodeling in adolescence and adulthoodPubMed: 25999830
  • Sex differences, learning flexibility, and striatal dopamine D1 and D2 following adolescent drug exposure in ratsPubmed:27091300
  • Evaluation of the effect of herbal extracts and their bioactive compounds against motion sickness by regulating neurotransmitter levels in vitro and in vivo
  • Benefit, Burdens and Brain Correlates of Heightened Reward Sensitivity in Adolescence
  • The GLP-1/GIP dual receptor agonist DA5-CH is superior to Exendin-4 in protecting neurons in the 6-OHDA rat Parkinson Model
  • ВЛИЯНИЕ ХРОНИЧЕСКОГО ВВЕДЕНИЯ НЕЙРОЛЕПТИКОВ НА УРОВНИ НЕЙРОСПЕЦИФИЧЕСКИХ АУТОАНТИТЕЛ В КРОВИ У КРЫС
  • Menthol, a bioactive constituent of Mentha, attenuates motion sickness in mice model: Involvement of dopaminergic system34245039

Recommend products